August 2026 · Real-world pharma task · Verified claim

PDT THERAPY F2

Photodynamic therapy agent selection on IBM Kingston — a pre-registered multi-logic expectation, scored PASS on raw QPC readout. Not “the job ran.” A real-world result.

Plain English

What this task is
Choose among five therapy-only PDT drugs under three goals at once: efficacy, toxicity, and selectivity. Detection/guidance agents were excluded.
What we expected (locked before the run)
talaporfin (Laserphyrin) must outrank padeliporfin (Tookad) on QPC multi-logic priority — because mono-efficacy says so, while a simple equal-weight average says the opposite.
What QPC computed
One coupled quantum job on ibm_kingston · 18 qubits · 4096 shots · raw counts primary · public job ID below.
Headline result
PASS — talaporfin priority 0.546 > padeliporfin 0.493. The claim was verified.
What we claim — and do not
Claim: this pre-registered ranking expectation held on QPC hardware. Do not claim: a clinical prescription, VQE chemistry, or that every PDT claim will pass.

Verdict

PASS — expectation F2-E1 verified

QPC ranked talaporfin_sodium above padeliporfin on coupled raw multi-logic priority, against equal-weight classical on the same proxies.

PASS
Claim verdict
0.546
Talaporfin priority
0.493
Padeliporfin priority
+0.053
Margin

Why this counts as a real result

Classical contrast (same proxies)

Method Order on the pair
Mono-efficacy talaporfin > padeliporfin
Equal-weight average padeliporfin > talaporfin
QPC coupled raw (this job) talaporfin > padeliporfin — PASS

Full QPC ranking (therapy-only panel)

Rank Agent Priority
1verteporfin (Visudyne)0.609
2talaporfin_sodium (Laserphyrin)0.546
3padeliporfin (Tookad)0.493
4temoporfin (Foscan)0.435
5porfimer_sodium (Photofrin)0.414

Job record

FieldValue
Backendibm_kingston (Heron · open plan)
Job IDda0bkvv2sl0c73bmtf2g
Shots4096
Geometry5 agents × 3 logics + 3 junctions = 18 qubits
Primary metricF2-E1 claim verdict on coupled raw priority
HonestyArchitecture research on frozen public proxies — not a prescribing tool

An earlier full-panel claim (E1: keep hexaminolevulinate out of top-3) scored FAIL — a real negative finding. Setup F2 is the therapy-only redesign that delivered this verified PASS.

← Highlights Real-World Desks